CERT Certara Inc

$11.47

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About Certara Inc

Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.

Website: https://www.certara.com

Sector
TECHNOLOGY
Industry
SERVICES-PREPACKAGED SOFTWARE
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1827090
Address
100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, US
Valuation
Market Cap
$2.28B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.16
Performance
EPS
$-0.08
Dividend Yield
Profit Margin
-3.13%
ROE
-1.15%
Technicals
50D MA
$11.78
200D MA
$12.01
52W High
$17.94
52W Low
$8.63
Fundamentals
Shares Outstanding
161M
Target Price
$15.11
Beta
1.64

CERT EPS Estimates vs Actual

Estimated
Actual

CERT News & Sentiment

Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Certara ( CERT ) Q2 Revenue Jumps 12%
Certara ( NASDAQ:CERT ) , a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue beat, with reported GAAP revenue of $104.6 million, exceeding analyst expectations, but ...
Aug 06, 2025 • Zacks Commentary NEUTRAL
Certara, Inc. ( CERT ) Q2 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 04, 2025 • GlobeNewswire NEUTRAL
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara today announced that the European Medicines Agency has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.
Aug 04, 2025 • Benzinga NEUTRAL
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - Certara ( NASDAQ:CERT )
RADNOR, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency ( EMA ) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA ...
Jul 31, 2025 • GlobeNewswire BULLISH
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
RADNOR, Pa., July 31, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. ( Nasdaq: CERT ) , a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer.
Jul 31, 2025 • Benzinga SOMEWHAT-BULLISH
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform - Certara ( NASDAQ:CERT )
RADNOR, Pa., July 31, 2025 ( GLOBE NEWSWIRE ) -- Certara, Inc. CERT, a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer.
Sentiment Snapshot

Average Sentiment Score:

0.175
50 articles with scored sentiment

Overall Sentiment:

Bullish

CERT Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $0.15
  • Estimate: $0.13
  • Whisper:
  • Surprise %: 19.6%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.13
  • Estimate: $0.11
  • Whisper:
  • Surprise %: 18.2%
Aug 06, 2024
Jun 30, 2024 (Post market)
-0.03 Surprise
  • Reported EPS: $0.07
  • Estimate: $0.10
  • Whisper:
  • Surprise %: -30.0%
May 07, 2024
Mar 31, 2024 (Post market)
0.0 Surprise
  • Reported EPS: $0.10
  • Estimate: $0.10
  • Whisper:
  • Surprise %: 0.0%
Feb 29, 2024
Dec 31, 2023 (Post market)
-0.02 Surprise
  • Reported EPS: $0.09
  • Estimate: $0.11
  • Whisper:
  • Surprise %: -18.2%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $0.11
  • Estimate: $0.11
  • Whisper:
  • Surprise %: 0.0%
Aug 09, 2023
Jun 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.13
  • Whisper:
  • Surprise %: -7.7%
May 08, 2023
Mar 31, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.12
  • Whisper:
  • Surprise %: 0.0%

Financials